DOES THE LIPID PROFILE DEPEND ON THE COMORBIDITY OF OVERWEIGHT/OBESITY AND ARTERIAL HYPERTENSION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS?
DOI:
https://doi.org/10.11603/bmbr.2706-6290.2021.3.12560Keywords:
type 2 diabetes mellitus, overweight, obesity, hypertension, comorbidity, lipid profileAbstract
Summary. Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in patients with diabetes mellitus who have 2–4 times higher risk of CVD compared with non-diabetics.
The aim of the study – to analyze the dependence of lipid profile changes on the comorbidity of overweight/obesity and hypertension in patients with type 2 diabetes mellitus.
Materials and Methods. For the purpose of retrospective analysis of medical records, 579 patients with type 2 diabetes mellitus (T2DM) were included depending on comorbidity: overweight/obesity and arterial hypertension (AH). Verification of T2DM was performed in accordance with the recommendations of the American Diabetes Association (2019). The diagnosis of stage 1 arterial hypertension (AH) was established according to the ESC/ESH recommendations for AH in 2018. Serum lipid profile was measured using commercially available kits on a Cobas 6000 analyzer (Roche Hitachi, Germany).
Results. In patients with comorbid T2DM, obesity and AH, changes in the lipid profile were characterized by significantly higher values of total cholesterol (18.3 %), triglycerides (93.1 %) and residual cholesterol (76.9 %) relative to data with T2DM. Analysis of lipid metabolism in patients with T2DM depending on the presence of hypertension showed a significantly higher concentration of total cholesterol and triglycerides in patients with T2DM with AH, relative to data without AH (p = 0.04). Analysis of lipid metabolism in patients with T2DM depending on the degree of overweight showed that in patients with T2DM with overweight/obesity, lipidogram data are significantly higher than in patients with normal body weight, in particular, the concentration of total cholesterol (15.0 % and 11.8 %), triglycerides (by 43.3 % and 67.2 %), non-cholesterol HDL (by 17.7 % and 15.0 %) and residual cholesterol (by 35.6 % and 52.9 %) respectively.
Conclusions. In patients with type 2 diabetes, both hypertension and overweight affect the severity of dyslipidemia.
References
Hevko U, Kozak K, Krynytska I, Marushchak M. Diagnostic value of a complete blood count in type 2 diabetes mellitus and comorbidities. Archives of the Balkan Medical Union. 2020;55(4): 601-7.
Hevko U, Marushchak M. [Genetics of type 2 diabetes mellitus and its combination with obesity and chronic pancreatitis]. Med i klin khim. 2020;4;103-13.
Hinge CR, Ingle SB, Adgaonkar BD. Body mass index, blood pressure and lipid profile in type 2 diabetes-review. Int J Cur Res Rev. 2018;10(10): 1-9.
Jayakumari C, Jabbar PK, Soumya S. Lipid profile in Indian patients with type 2 diabetes: The scope for atherosclerotic cardiovascular disease risk reduction. Diabetes Spectrum. 2020;33(4): 299-306.
(ADA) American Diabetes Association. Standards of Medical Care in Diabetes – 2019 abridged for primary care providers. Clin Diabetes. 2019;1(37): 11-34.
Williams B, Mancia G, Spiering W. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018; 39(33): 3021-104.
Body Mass Index: Considerations for Practitioners. URL: https://www.cdc.gov/obesity/downloads/bmiforpactitioners.pdf.
Piepoli MF, Hoes AW, Agewall S. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). European Heart Journal. 2016;37(29): 2315-81.
Gordon L, Ragoobirsingh D, Morrison EY, Choo-Kang E, McGrowder D, Martorell E. Lipid profile of type 2 diabetic and hypertensive patients in the jamaican population. J Lab Physicians. 2010;2(1): 25-30. DOI: 10.4103/0974-2727.66709. PMID: 21814403; PMCID: PMC3147082.
Lamarche B, Després JP, Moorjani S, Cantin B, Dagenais GR, Lupien PJ. Triglycerides and HDL-cholesterol as risk factors for ischemic heart disease. Results from the Québec cardiovascular study. Atherosclerosis. 1996;119(2): 235-45.
Yarema N, Kotsiuba O, Krytskyy T, Marushchak M, Krynytska I. Peculiarities of arterial hypertension in postmenopausal women with bone mineral density disorders and dyslipidemia. Polish medical journal. 2020;XLVIII(283): 5-9.
Rizzo M, Berneis K. Lipid triad or atherogenic lipoprotein phenotype: A role in cardiovascular prevention. J Atherosclerosis Thromb. 2005;12(5): 237-9.
Evans M, Roberts A, Davies S, Rees A. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Drugs. 2004;64: 1181-96.
Dean BB, Borenstein JE, Henning JM, Knight K, Merz CN. Can change in high-density lipoprotein cholesterol levels reduce cardiovascular risk? Am Heart J. 2004;147(6): 939-41.
Steven HM, Seppo L, Tapani R, Kalevi P, Markku L. Mortality from coronary heart disease in subjects with type II diabetes Mellitus and nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4): 229-34.
Preis SR, Pencina MJ, Hwang SJ. Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart study. Circulation. 2009;120: 212-20.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Bulletin of Medical and Biological Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
